Possibia

2836613

Last Update Posted: 2019-03-13

Recruiting has ended

All Genders

accepted

18 Years-65 Years

160 Estimated Participants

No Expanded Access

Interventional Study

Accepts healthy volunteers

A Study of Galcanezumab in Healthy Participants.

The main purpose of this study is to evaluate how much galcanezumab gets into the body after it is given as an injection just under the skin by two different devices. This study will measure how much galcanezumab reaches the blood stream and will test how it affects calcitonin-gene related peptide (CGRP) in blood. Information about any side effects that may occur will be collected. The study will last about 20 weeks for each participant. Screening is required within 45 days prior to the start of the study.

Eligibility

Relevant conditions:

Healthy

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Data sourced from ClinicalTrials.gov